PT Saptausaha Gemilangindah Tbk (SAGE)
Jul 31, 2025 - SAGE was delisted (reason: acquired by SUPN)
8.68
-0.02 (-0.23%)
Inactive · Last trade price on Jul 30, 2025
Sage Therapeutics Employees
PT Saptausaha Gemilangindah Tbk had 353 employees as of December 31, 2024. The number of employees decreased by 134 or -27.52% compared to the previous year.
Employees
353
Change (1Y)
-134
Growth (1Y)
-27.52%
Revenue / Employee
$10,191
Profits / Employee
-$3,391
Market Cap
9.32M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 353 | -134 | -27.52% |
| Dec 31, 2023 | 487 | -202 | -29.32% |
| Dec 31, 2022 | 689 | 218 | 46.28% |
| Dec 31, 2021 | 471 | 173 | 58.05% |
| Dec 31, 2020 | 298 | -377 | -55.85% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
SAGE News
- 4 weeks ago - Sage Therapeutics Announces Second Quarter 2025 Financial Results - Business Wire
- 6 weeks ago - SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE - Business Wire
- 2 months ago - Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary - GlobeNewsWire
- 2 months ago - These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News - Benzinga
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect - Accesswire
- 2 months ago - Top 3 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga
- 2 months ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc. - PRNewsWire
- 2 months ago - Sage Therapeutics Stock Soars 35% After Sale to Supernus. What We Know. - Barrons